• Je něco špatně v tomto záznamu ?

Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: Insights from 1544 patients included in the SOURCE 3 registry

N. Dumonteil, C. Terkelsen, C. Frerker, F. Collart, J. Wöhrle, C. Butter, T. Hovorka, F. Pinaud, H. Baumgartner, G. Tarantini, O. Wendler, T. Lefèvre, SOURCE 3 Investigators,

. 2019 ; 296 (-) : 32-37. [pub] 20190612

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025434

AIMS: To investigate the impact of transcatheter aortic valve replacement (TAVR) without preliminary balloon aortic valvuloplasty (pre-BAV) on periprocedural outcomes in a large, real-world registry. METHODS AND RESULTS: The SOURCE 3 registry was an observational, multi-center, single-arm study of patients with severe, symptomatic aortic stenosis at high surgical risk treated with the SAPIEN 3 transcatheter heart valve (THV). Procedural and 30-day outcomes were compared between two groups of 772 patients each (retrospectively matched) with or without pre-BAV. All baseline clinical, echocardiographic, and anatomical valve characteristics were comparable between groups except for Society of Thoracic Surgeons (STS) score, which was lower in the direct TAVR group (6.0 ± 5.9 vs 7.8 ± 8.3; p = 0.003). In the direct TAVR group, there were less post-dilatations (8.1% vs. 13.1%, p = 0.002), shorter procedural time (70.9 ± 39.8 min vs 73.0 ± 32.2 min, p = 0.033) and fluoroscopy time (13.4 ± 7.0 min vs 14.9 ± 7.4 min, p < 0.001). Other procedural outcomes and echocardiographic variables at 30 days did not differ significantly between the two groups: safety endpoint (10.4% with pre-BAV vs 13.5% with direct TAVR, p = 0.059), mortality (2.1% vs 2.3%, p = 0.730), disabling strokes (0.4% vs 0.5%, p = 0.704), and moderate to severe paravalvular leak (PVL) (3.2% vs 2.2%, p = 0.40). Unexpectedly, new permanent pacemaker implantation and life-threatening bleeds were less frequently observed with pre-BAV group than with direct TAVR (10.4% vs 13.9%, p = 0.032 and 3.5% vs 6.5%, p = 0.007, respectively). CONCLUSION: In this large TAVR dataset, direct implantation of the SAPIEN 3 THV without pre-BAV was feasible and safe and resulted in shorter procedures, without impact on 30-day prosthesis function and PVL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025434
003      
CZ-PrNML
005      
20201222160216.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2019.06.013 $2 doi
035    __
$a (PubMed)31256993
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Dumonteil, Nicolas $u Groupe CardioVasculaire Interventionnel (GCVI), Clinique Pasteur, Toulouse, France. Electronic address: ndumonteil@clinique-pasteur.com.
245    10
$a Outcomes of transcatheter aortic valve replacement without predilation of the aortic valve: Insights from 1544 patients included in the SOURCE 3 registry / $c N. Dumonteil, C. Terkelsen, C. Frerker, F. Collart, J. Wöhrle, C. Butter, T. Hovorka, F. Pinaud, H. Baumgartner, G. Tarantini, O. Wendler, T. Lefèvre, SOURCE 3 Investigators,
520    9_
$a AIMS: To investigate the impact of transcatheter aortic valve replacement (TAVR) without preliminary balloon aortic valvuloplasty (pre-BAV) on periprocedural outcomes in a large, real-world registry. METHODS AND RESULTS: The SOURCE 3 registry was an observational, multi-center, single-arm study of patients with severe, symptomatic aortic stenosis at high surgical risk treated with the SAPIEN 3 transcatheter heart valve (THV). Procedural and 30-day outcomes were compared between two groups of 772 patients each (retrospectively matched) with or without pre-BAV. All baseline clinical, echocardiographic, and anatomical valve characteristics were comparable between groups except for Society of Thoracic Surgeons (STS) score, which was lower in the direct TAVR group (6.0 ± 5.9 vs 7.8 ± 8.3; p = 0.003). In the direct TAVR group, there were less post-dilatations (8.1% vs. 13.1%, p = 0.002), shorter procedural time (70.9 ± 39.8 min vs 73.0 ± 32.2 min, p = 0.033) and fluoroscopy time (13.4 ± 7.0 min vs 14.9 ± 7.4 min, p < 0.001). Other procedural outcomes and echocardiographic variables at 30 days did not differ significantly between the two groups: safety endpoint (10.4% with pre-BAV vs 13.5% with direct TAVR, p = 0.059), mortality (2.1% vs 2.3%, p = 0.730), disabling strokes (0.4% vs 0.5%, p = 0.704), and moderate to severe paravalvular leak (PVL) (3.2% vs 2.2%, p = 0.40). Unexpectedly, new permanent pacemaker implantation and life-threatening bleeds were less frequently observed with pre-BAV group than with direct TAVR (10.4% vs 13.9%, p = 0.032 and 3.5% vs 6.5%, p = 0.007, respectively). CONCLUSION: In this large TAVR dataset, direct implantation of the SAPIEN 3 THV without pre-BAV was feasible and safe and resulted in shorter procedures, without impact on 30-day prosthesis function and PVL.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a dilatace $7 D004106
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a předoperační péče $7 D011300
650    _2
$a prospektivní studie $7 D011446
650    _2
$a registrace $7 D012042
650    _2
$a transkatetrální implantace aortální chlopně $x metody $7 D065467
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Terkelsen, Christian $u Aarhus University Hospital, Skejby, Denmark.
700    1_
$a Frerker, Christian $u Asklepios Clinic, Hamburg, Germany.
700    1_
$a Collart, Frederic $u University Hospital La Timone, Marseille, France.
700    1_
$a Wöhrle, Jochen $u Department of Internal Medicine II - Cardiology, University Hospital of Ulm, Ulm, Germany.
700    1_
$a Butter, Christian $u Herzzentrum Brandenburg, Bernau, Germany.
700    1_
$a Hovorka, Tomas $u Edwards Lifesciences, Prague, Czech Republic.
700    1_
$a Pinaud, Frederic $u University Hospital, Angers, France.
700    1_
$a Baumgartner, Helmut $u University Hospital, Münster, Germany.
700    1_
$a Tarantini, Giuseppe $u Padova Hospital, Italy.
700    1_
$a Wendler, Olaf $u King's College Hospital London, United Kingdom.
700    1_
$a Lefèvre, Thierry $u Private Hospital Jacques Cartier, Massy, France.
710    2_
$a SOURCE 3 Investigators
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 296, č. - (2019), s. 32-37
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31256993 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160212 $b ABA008
999    __
$a ok $b bmc $g 1599579 $s 1116120
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 296 $c - $d 32-37 $e 20190612 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace